产品说明书
Cisplatin
 |
同义名 : | 顺-二胺二氯铂(II) ;cis-Platinum;CDDP;CACP;cis-Diamminedichloroplatinum;DDP;cis DDP;cis-diamminedichloroplatinum II;NSC 119875;cis-Diaminodichloroplatinum |
| CAS号 : | 15663-27-1 | |
| 货号 : | A210558 | |
| 分子式 : | Cl2H6N2Pt | |
| 纯度 : | 99% | |
| 分子量 : | 300.045 | |
| MDL号 : | MFCD00011623 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
H2O: 1 mg/mL(3.33 mM)，配合低频超声，并水浴加热至45℃助溶 DMF: 10 mg/mL(33.33 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
PO 0.5% CMC-Na 85 mg/mL suspension |
| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Cisplatin (CDDP) is an antineoplastic chemotherapy agent, primarily by forming cross-links with DNA and thus inflicting DNA damage within cancer cells. Cisplatin triggers ferroptosis and induce autophagy, contributing to its effectiveness against various cancer types[1].[2].[3]. | ||
| 作用机制 | Reaction with DNA by culminating in either repair of the DNA damage and cell survival or activation of the irreversible apoptotic program[1]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02128282 | Cholangiocarcinoma | Phase 1 Phase 2 | Recruiting | November 2021 | United States, Arizona ... 展开 >> Mayo Clinic Recruiting Scottsdale, Arizona, United States, 85259-5499 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Mitesh Borad, M.D. United States, Colorado University of Colorado- Denver Recruiting Aurora, Colorado, United States, 80045 Contact: Amy Szilard 720-848-0702 Amy.Szilard@ucdenver.edu Principal Investigator: Sarah (Lindsey) Davis, MD United States, Florida Mayo Clinic Recruiting Jacksonville, Florida, United States, 32224 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Kabir Mody, MD United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Joleen Hubbard, MD United States, Texas Texas Oncology - Baylor Charles A. Sammons Cancer Center Recruiting Dallas, Texas, United States, 75246 Contact: Tammy Carmical, RN 214-370-1937 tammy.carmical@usoncology.com Principal Investigator: Carlos Becerra, M.D. Texas Oncology-Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Karen Poe, RN 903-579-9869 karen.poe@usoncology.com Principal Investigator: Donald A Richards, M.D. Korea, Republic of Asan Medical Center Recruiting Seoul, Songpa-gu, Korea, Republic of, 138-736 Contact: Heung-Moon Chang, MD 82-3010-3219 ext 3210 changhm@amc.seoul.kr Contact: Seok kyung Jeong 82-2-3010-5634 jsk0213@amc.seoul.kr Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Eunyou Lee 82-2-3410-0955 ley0709@samsung.com Principal Investigator: Joon Oh Park, MD Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Myoungsun Choi 82-2-2072-7612 iamyou3@hanmail.net Principal Investigator: Do-Youn Oh, MD Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of Contact: So Young Hwang 82-2-2228-8180 syhwang@yuhs.ac Principal Investigator: Sun Young Rha, MD Taiwan China Medical University Hospital Recruiting Taichung City, Taiwan Contact: Pei-Chen Hsu +886-4-2205-2121 peggyshiu0807@gmail.com Principal Investigator: Li-Yuan Bai, M.D. 收起 << |
| NCT00915382 | Advanced Gastric Cancer | Phase 3 | Completed | - | Korea, Republic of ... 展开 >> Department of Oncology, Asan Medical Center Seoul, Korea, Republic of, 138-736 收起 << |
| NCT03427359 | Nasopharyngeal Carcinoma | Phase 2 | Completed | - | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.33mL 0.67mL 0.33mL |
16.66mL 3.33mL 1.67mL |
33.33mL 6.67mL 3.33mL |
| 参考文献 |
|---|